One important risk factor for cardiovascular disease is the metabolic syndrome (MS), yet
limited data exist on its prevalence in US patients with schizophrenia. METHODS: Using …

OBJECTIVE: Standardized mortality rates are elevated in schizophrenia compared to the
general population. The incidence of coronary heart disease (CHD) and the relative …

BACKGROUND: The metabolic syndrome (MS) is associated with increased risk for diabetes
mellitus and coronary heart disease, and is highly prevalent among schizophrenia patients. …

Persons diagnosed with schizophrenia have higher morbidity and mortality rates from
cardiovascular disease, yet often have limited access to appropriate primary care screening or …

Several antipsychotics are associated with the ventricular tachycardia torsade de pointes (TdP),
which may lead to sudden cardiac death (SCD), because of their inhibition of the cardiac …

Objectives: The purpose of this paper is to review the literature since 1970 documenting the
effects of antipsychotic agents on serum lipids, including a discussion of possible …

… Twenty-eight physicians and psychiatrists, including editors Jonathan M. Meyer, MD, and
Henry A. Nasrallah, MD, lend their expertise to this new, expanded edition. In fifteen chapters, …

Real-world and clinical trial data support that clozapine is the only effective antipsychotic for
treatment resistant schizophrenia and other severe mental illnesses. Clozapine also …

Guidelines for treating various conditions can be helpful in setting practice standards, but the
presence of several sets of guidelines from different countries, experts, and settings, written …

Background: Metabolic side effects have been increasingly noted during therapy with novel
antipsychotics, but there is a dearth of comprehensive comparative data in this area. The …